Richter's Syndrome Diagnosis Using Cell-Free DNA Sequencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Richter's Syndrome (RS) from chronic lymphocytic leukemia (CLL) are limited by sample acquisition challenges, admixture of CLL and RS cells in biopsies, and lack of robust computational tools for deconvolution, leading to incomplete understanding of genetic drivers and molecular features, resulting in high misdiagnosis rates and poor clinical management.
Innovation Solution
A method involving nucleic acid sequencing and analysis of specific mutations in genes such as TP53, NOTCH1, IRF2BP2, DNMT3A, SRSF1, EZH2, CCND3, TET2, IRF8, MYC, and PIM1, along with genomic alterations, to distinguish RS from CLL and identify RS subtypes, using cell-free DNA from blood, serum, or plasma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional pathology morphologic assessment is used to diagnose Richter's Syndrome, then the diagnosis can be performed, but the misdiagnosis rate increases to up to 20%
Solution Approach 1:
The patent replaces traditional pathology morphologic assessment with molecular genetic testing. Specifically, it uses sequencing analysis to detect somatic mutations in genes such as TP53, NOTCH1, IRF2BP2, DNMT3A, SRSF1, EZH2, CCND3, TET2, IRF8, MYC, and PIM1. This molecular approach provides higher diagnostic accuracy and reduces misdiagnosis rates by directly detecting the genetic alterations that define Richter's Syndrome, rather than relying on morphologic assessment alone.
Solution Approach 2:
The patent changes the diagnostic parameter from morphologic appearance to genetic mutation detection. By shifting the detection target from cellular morphology to specific somatic mutations in key genes, the method achieves more reliable diagnosis. The presence or absence of specific mutations (e.g., TP53 mutations, NOTCH1 mutations) serves as a binary diagnostic marker that clearly distinguishes Richter's Syndrome from other lymphomas and from transformed CLL.
2Quantity of substance
If biopsy samples are used for genetic analysis, then tissue DNA can be obtained, but the samples are comprised of admixtures of RS and CLL cells making deconvolution difficult
Solution Approach 1:
The patent segments the diagnostic approach into two parts: (1) detecting somatic mutations that are specific to Richter's Syndrome transformation events, and (2) detecting copy number alterations characteristic of RS. By focusing on RS-specific mutations rather than attempting to deconvolute the entire admixed sample, the method simplifies the analysis while maintaining diagnostic accuracy. The segmentation allows detection of transformation-specific events without requiring complete separation of CLL and RS cell populations.
Solution Approach 2:
The patent uses cell-free DNA (cfDNA) from plasma as an intermediary medium to obtain genetic material. Instead of directly analyzing complex tissue biopsies that contain admixtures of CLL and RS cells, the method extracts cfDNA from plasma, which provides a simplified source of genetic material for mutation detection. This intermediary approach avoids the computational deconvolution challenges of tissue samples while still enabling detection of RS-specific mutations.
3Loss of information
If comprehensive genomic study of RS is performed, then genetic drivers can be identified, but sample acquisition becomes more difficult due to the rapidly progressive nature of the malignancy
Solution Approach 1:
The patent performs preliminary molecular characterization by detecting somatic mutations and copy number alterations in readily available samples (blood, plasma, urine) at the time of diagnosis. This preliminary action captures the genetic landscape of RS before the disease progresses further or the patient deteriorates. By using easily obtainable liquid samples rather than requiring complex tissue biopsies, the method enables timely genetic profiling without delaying diagnosis or treatment.
4Loss of information
If paired antecedent CLL samples are available, then comparative evolutionary analysis can be performed, but such paired samples are rarely available in practice
Solution Approach 1:
The patent creates a universal diagnostic method that can be applied to any RS sample regardless of whether paired antecedent CLL samples are available. The method detects somatic mutations and copy number alterations that are specific to RS transformation, making it applicable to both paired and unpaired samples. This universality allows the method to function effectively in real-world scenarios where paired historical samples are rarely available, while still providing comprehensive genetic characterization of the RS transformation.
Data Source
AI summary
Disclosed herein are methods and devices for use in early detection of Richter's Syndrome. The methods include sequencing a panel of regions in cell-free DNA molecules and detecting one or more markers that are indicative of Richter's Syndrome.